MONCTON, NEW BRUNSWICK–(Marketwired – Aug. 9, 2017) – Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF) (the “Company” or “Organigram“) is pleased to announce that it will be presenting at the Canaccord Genuity 37th Annual Growth Conference, on Thursday, August 10, 2017.
Greg Engel, Chief Executive Officer of Organigram will present to conference attendees beginning at 10:30 am EDT in the Hong Kong Room of the InterContinental Boston Hotel located at 510 Atlantic Avenue in Boston. Mr. Engel will also conduct a series of one-on-one meetings with institutional investors. Registered attendees interested in scheduling a meeting with management should contact conference coordinators.
Further, the Company announces that subject to the approval of the TSX Venture Exchange (the “TSXV“), the Company shall issue 40,000 Common Shares in the capital of Organigram to 9250-5999 Québec Inc. (the “Consultant“), a company wholly-owned by Steve Abboud, a recognized marijuana cultivation expert, pursuant to a Consultant Agreement whereby the Consultant provided consulting and advisory services in respect to the cultivation of marijuana and related matters. The Common Shares will be issued at a price of $2.29 per share. Any issuance of shares will be subject to applicable hold periods required under securities laws.
Additionally, the Company is pleased to announce that the Consultant will continue to provide marijuana cultivation consulting services, including advising on ongoing expansion matters, until December 2018. As part of this arrangement, the Consultant will be entitled to an issuance of up to $45,000 in common shares of the Company, based on the closing price of the shares on the last trading day prior to the issuance, every three months that the services are performed, and an issuance of up to $125,000 in bonus shares in December 2018 provided that certain milestones have been attained during the term of this arrangement.
For more information, visit www.Organigram.ca
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).
Organigram has been ranked in the top ten Clean Technology & Life Sciences Sector on the TSX Venture Exchange 50.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, crop yields – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
Greg Engel
Chief Executive Officer
gengel@organigram.ca
Organigram Holdings Inc.
Giselle Doiron
Director of Investor and Media Relations
(506) 801-8986